Please upgrade your browser.
Visit spurs Mass. General doctor to pursue treatment
Early tumor shrinkage in patients with metastatic renal cell carcinoma (mRCC) following vascular endothelial growth factor (VEGF)-targeted therapy may herald good long-term survival, research shows.
Low serum sodium levels in patients receiving targeted therapy for metastatic renal cell carcinoma (mRCC) may signal a poor outcome, study findings indicate.
First-line therapy with Inlyta® (axitinib) demonstrated clinical activity in metastatic renal cell carcinoma, according to the results of a study published in The Lancet Oncology.
"We prospectively assessed the efficacy and safety of axitinib dose titration in previously untreated patients with metastatic renal-cell carcinoma. In this randomised, double-blind, multicentre, phase 2 study, patients were enrolled from 49 hospitals and outpatient clinics in the Czech Republic, Germany, Japan, Russia, Spain, and USA. Patients with treatment-naive metastatic renal-cell carcinoma received axitinib 5 mg twice daily during a 4 week lead-in period..."
One of the most potent forms of immunotherapy for patients with metastatic melanoma and renal cell carcinoma is high-dose (HD) bolus IL-2 therapy. Approximately 15% of patients respond to HD IL-2 therapy, with almost 5% going into complete remission;..
Impact of fusion subtype, age, and stage
Portland-area researchers have scored promising results in the hottest field in cancer research today: Using the immune system to fight tumors.
Portland-area researchers harness immune system to shrink tumors
A boy with a rare type of cancer who had his health insurance plan canceled after the Affordable Care Act took effect...
|Powered by NeonCRM|